Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 3;7(7):CD012002.
doi: 10.1002/14651858.CD012002.pub2.

Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)

Petra Vayne-Bossert  1 , Alison Haywood, Phillip Good, Sohil Khan, Kirsty Rickett, Janet R Hardy
Affiliations
Meta-Analysis

Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)

Petra Vayne-Bossert et al. Cochrane Database Syst Rev. .

Abstract

Background: Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%. While nausea and vomiting can be related to cancer treatments, such as chemotherapy, radiotherapy, or surgery, a significant number of people with advanced cancer also suffer from nausea unrelated to such therapies. Nausea and vomiting may also cause psychological distress, and have a negative impact on the quality of life of cancer patients; similarly to pain, nausea is often under-treated. The exact mechanism of action of corticosteroids on nausea is unclear, however, they are used to manage a number of cancer-specific complications, including spinal cord compression, raised intracranial pressure, and lymphangitis carcinomatosis. They are also commonly used in palliative care for a wide variety of non-specific indications, such as pain, nausea, anorexia, fatigue, and low mood. However, there is little objective evidence of their efficacy in symptom control, and corticosteroids have a wide range of adverse effects that are dose and time dependent. In view of their widespread use, it is important to seek evidence of their effects on nausea and vomiting not related to cancer treatment.

Objectives: To assess the effects of corticosteroids on nausea and vomiting not related to chemotherapy, radiotherapy, or surgery in adult cancer patients.

Search methods: We searched CENTRAL, MEDLINE Ovid, Embase Ovid, CINAHL EBSCO, Science Citation Index Web of Science, Latin America and Caribbean Health Sciences (LILACS), Conference Proceedings Citation Index - Science Web of Science, and clinical trial registries, from inception to 23rd August 2016.

Selection criteria: Any double-blind randomised or prospective controlled trial that included adults aged 18 years and over with advanced cancer with nausea and vomiting not related to chemotherapy, radiotherapy, or surgery were eligible for the review, when using corticosteroids as antiemetic treatment.

Data collection and analysis: All review authors independently assessed trial quality and extracted data. We used arithmetic means and standard deviations for each outcome to report the mean difference (MD) with 95% confidence interval (CI). We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table.

Main results: Three studies met the inclusion criteria, enrolling 451 participants. The trial size varied from 51 to 280 participants. Two studies compared dexamethasone to placebo, and the third study compared a number of additional interventions in various combinations, including metoclopramide, chlorpromazine, tropisetron, and dexamethasone. The duration of the studies ranged from seven to 14 days. We included two studies (127 participants) with data at eight days in the meta-analysis for nausea intensity; no data were available that incorporated the same outcome measures for the third study. Corticosteroid therapy with dexamethasone resulted in less nausea (measured on a scale of 0 to 10, with a lower score indicating less nausea) compared to placebo at eight days (MD 0.48 lower nausea, 95% CI 1.53 lower to 0.57 higher; very low-quality evidence), although this result was not statistically significant (P = 0.37). Frequency of adverse events was not significantly different between groups, and the interventions were well tolerated. Factors limiting statistical analysis included the lack of standardised measurements of nausea, and the use of different agents, dosages, and comparisons. Subgroup analysis according to type of cancer was not possible due to insufficient data. The quality of this evidence was downgraded by three levels, from high to very low due to imprecision, likely selection bias, attrition bias, and the small number of participants in the included studies.

Authors' conclusions: There are few studies assessing the effects of corticosteroids on nausea and vomiting not related to chemotherapy, radiotherapy, or surgery in adult cancer patients. This review found very low-quality evidence which neither supported nor refuted corticosteroid use in this setting. Further high quality studies are needed to determine if corticosteroids are efficacious in this setting.

PubMed Disclaimer

Conflict of interest statement

JH: none known; JH is a specialist palliative medicine physician and manages patients with nausea and vomiting due to advanced cancer. JH has authored a book “Opioids in cancer pain".

PVB: none known; PVB is a specialist palliative medicine physician and manages patients with nausea and vomiting due to advanced cancer.

PG: none known; PG is a specialist palliative medicine physician and manages patients with nausea and vomiting due to advanced cancer.

AH: none known.

SK: none known.

KR: none known.

Figures

1
1
PRISMA Study flow diagram
2
2
Risk of bias graph: review authors' judgements about each 'Risk of bias' domain, presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each 'Risk of bias' domain for each included study.
4
4
Forest plot of comparison: 1 Nausea, outcome: 1.1 Nausea at 8 days.
1.1
1.1. Analysis
Comparison 1 Nausea, Outcome 1 Nausea at 8 days.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012002

References

References to studies included in this review

Bruera 2004 {published data only}
    1. Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. Journal of Pain and Symptom Management 2004;28(4):381‐8. - PubMed
Mystakidou 1998 {published data only}
    1. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer 1998;83(6):1214‐23. - PubMed
Yennurajalingam 2013 {published data only}
    1. Yennurajalingam S, Frisbee‐Hume S, Palmer JL, Delgado‐Guay MO, Bull J, Phan AT, et al. Reduction of cancer‐related fatigue with dexamethasone: a double‐blind, randomized, placebo‐controlled trial in patients with advanced cancer. Journal of Clinical Oncology 2013;31(25):3076‐82. - PubMed

References to studies excluded from this review

Arvieux 2005 {published data only}
    1. Arvieux C, Laval G, Mestrallet JP, Stefani L, Villard ML, Cardin N. Treatment of malignant intestinal obstruction. A prospective study over 80 cases. Annales De Chirurgie 2005;130(8):470‐6. - PubMed
Bruera 1996 {published data only}
    1. Bruera E, Seifert L, Watanabe S, Babul N, Darke A, Harsanyi Z, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide‐based antiemetic regimen. Journal of Pain and Symptom Management 1996;11(3):147‐53. - PubMed
Currow 2012 {published data only}
    1. Currow D, Clark K, Cartmill J, Craig AS, Pather S, Plummer J, et al. A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction in people with advanced cancer. Palliative Medicine 2012;26(4):403.
Currow 2015 {published data only}
    1. Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, et al. Double‐blind, placebo‐controlled, randomized trial of octreotide in malignant bowel obstruction. Journal of Pain and Symptom Management 2015;49(5):814‐21. - PubMed
Feuer 2000 {published data only}
    1. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001219] - DOI - PMC - PubMed
Klein 2012 {published data only}
    1. Klein C, Stiel S, Bukki J, Ostgathe C. Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients. A systematic literature review. Schmerz 2012;26(5):587‐99. - PubMed
Laval 2006 {published data only}
    1. Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N. Protocol for the treatment of malignant inoperable bowel obstruction: A prospective study of 80 cases at Grenoble University Hospital Center. Journal of Pain and Symptom Management 2006;31(6):502‐12. - PubMed
Yennurajalingam 2012 {published data only}
    1. Yennurajalingam S, Frisbee‐ Hume S, Palmer JL, Delgado‐Guay M, Bull J, Reddy AS, et al. Dexamethasone and symptom distress: Results of a placebo controlled, double‐blind randomized controlled trial in patients with advanced cancer. Supportive Care in Cancer 2012;20:S234.

Additional references

Ballatori 2007
    1. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, et al. The impact of chemotherapy‐induced nausea and vomiting on health‐related quality of life. Supportive Care in Cancer 2007;15(2):179‐85. - PubMed
Chu 2014
    1. Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. European Journal of Pharmacology 2014;5(722):48‐54. - PubMed
Davis 2000
    1. Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Supportive Care in Cancer 2000;8(6):444‐52. - PubMed
De Oliveira 2013
    1. Oliveira GS, Castro‐Alves LJS, Ahmad S, Kendall MC, McCarthy RJ. Dexamethasone to prevent postoperative nausea and vomiting: An updated meta‐analysis of randomized controlled trials. Anesthesia and Analgesia 2013;116(1):58‐74. - PubMed
Fainsinger 1991
    1. Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T. Symptom control during the last week of life on a palliative care unit. Journal of Palliative Care 1991;7(1):5‐11. - PubMed
Farr 1990
    1. Farr WC. The use of corticosteroids for symptom management in terminally ill patients. American Journal of Hospice Care 1990;7(1):41‐6. - PubMed
Feyer 1998
    1. Feyer PC, Stewart Al, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Supportive Care in Cancer 1998;6:253‐60. - PubMed
Foubert 2005
    1. Foubert J, Vaessen G. Nausea: the neglected symptom?. European Journal of Oncology Nursing 2005;9:21‐32. - PubMed
Gan 2007
    1. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist‐based pharmacotherapy. CNS Drugs 2001;21(10):813‐33. - PubMed
Gannon 2002
    1. Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. Journal of Pain and Symptom Management 2002;24(3):328‐34. - PubMed
Glare 2004
    1. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far‐advanced cancer. Supportive Care in Cancer 2004;12:432‐40. - PubMed
GRADEpro GDT 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro Guideline Development Tool (GRADEpro GDT). Version accessed 21 October 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Gralla 1999
    1. Gralla RJ, Osoba D, Kris MG. Recommendations for the use of antiemetics: evidence‐based clinical practice guidelines. Journal of Clinical Oncology 1999;17:2971‐94. - PubMed
Grunberg 2007
    1. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing,efficacy, and tolerability analysis. Annals of Oncology 2007;18(2):233‐40. - PubMed
Hanks 2009
    1. Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S, Portenoy R (editors). Oxford Textbook of Palliative Care. 4th Edition. Oxford: Oxford Press, 2009.
Hardy 2001
    1. Hardy J, Rees E, Ling J, Stone P, Burman R, Feuer D, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliative Medicine 2001;15:3‐8. - PubMed
Hardy 2015
    1. Hardy JR, Glare P, Yates Patsy, Mannix KA. Palliation of nausea and vomiting, Section 10.2. In: Cherny N, Fallon M, Kaasa S, Portenoy RK, Currow DC editor(s). Oxford Textbook of Palliative Medicine. 5th Edition. Oxford: Oxford University Press, 2015.
Harris 2010
    1. Harris DG. Nausea and vomiting in advanced cancer. British Medical Bulletin 2010;96:175‐85. - PubMed
Haywood 2015
    1. Haywood A, Good P, Khan S, Leupp A, Jenkins‐Marsh S, Rickett K, et al. Corticosteroids for the management of cancer‐related pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD010756.pub2] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hursti 1993
    1. Hursti TJ, Fredrikson M, Steineck G, Borjeson S, Furst CJ, Peterson C. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. British Journal of Cancer 1993;68:112‐4. - PMC - PubMed
Ioannidis 2000
    1. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control chemotherapy‐induced nausea and vomiting: a meta‐analysis of randomized evidence. Journal of Clinical Oncology 2000;18(19):3409‐22. - PubMed
Joss 1994
    1. Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy‐ naive and previously treated patients. Annals of Oncology 1994;5:253‐8. - PubMed
Latreille 1998
    1. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1998;16:1174‐8. - PubMed
Laval 2000
    1. Laval G, Girardier J, Laussauumiere J, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?. Palliative Medicine 2000;14:3‐10. - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65‐94. - PubMed
Mantovani 1997
    1. Mantovani G, Maccio A, Massa E, Lai P, Esu S. Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect. Oncology Reports 1997;4(5):1051‐3. - PubMed
Mercadante 2004
    1. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. Journal of Pain & Symptom Management 2004;28(4):412‐6. - PubMed
National Cancer Institute 2010
    1. National Cancer Institute. National Institute of Health, Department of Health and Human Services. Common Terminology Citeria for Adverse Events (CTCAE) v.4.0. Available from evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf 2010, issue accessed 6 June 2017.
Perugia Consensus Conference 1998
    1. Perugia Consensus Conference. Prevention of chemotherapy‐ and radiotherapy‐induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Annals of Oncology 1998;9(8):811‐9. - PubMed
Pirri 2013
    1. Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, et al. Nausea still the poor relation in antiemetictherapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Supportive Care in Cancer 2013;21(3):735‐48. - PubMed
Porternoy 1994
    1. Porternoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander‐Klar H, Coyle N, et al. Symptom prevalence, characteristics and distress in a cancer population. Quality of Life Research 1994;3(3):183‐9. - PubMed
Reuben 1986
    1. Reuben D. Nausea and vomiting in terminal cancer patients. Archives of Internal Medicine 1986;146(10):2021‐3. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Riechelmann 2007
    1. Riechelmann RP, Krzyanowska MK, O'Carrol A, Zimmermann C. Symptom and medication profiles among cancer patients attending a palliative care clinic. Supportive Care in Cancer 2007;15(12):1407‐12. - PubMed
Roila 2006
    1. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy‐ and radiotherapy‐induced emesis: results of the 2004 Perugia Internation Antiemetic Consensus Conference. Annals of Oncology 2006;17:20‐8. - PubMed
Smith 2005
    1. Smith HS. A receptor‐based paradigm of nausea and vomiting. Journal of Cancer Pain and Symptom Palliation 2005;1(1):11‐23.
Teunissen 2007
    1. Teunissen SC, Wesker W, Kruitwagen C, Haes HC, Voest EE, Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management 2007;34(1):94‐104. - PubMed
Walsh 2000
    1. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Supportive Care in Cancer 2000;8(3):175‐9. - PubMed

Publication types

MeSH terms

LinkOut - more resources